Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298106 | 0.89 | RAB9A (0.31) | HTTKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL27854967 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2HTTKMT2AALDH1A1LMNA | |
| SCHEMBL661279 | 0.83 | HPGD (0.37) | HTTKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL298638 | 0.69 | LMNA (0.32) | ALDH1A1LMNAHPGDL3MBTL1 | |
| SCHEMBL286895 | 0.68 | SMN1; SMN2 (0.34) | SMN1; SMN2MAPT | |
| SCHEMBL297985 | 0.66 | MAPT (0.35) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL287304 | 0.63 | HCAR2 (0.43) | ALDH1A1MAPTHPGD | |
| SCHEMBL287148 | 0.61 | ALDH1A1 (0.33) | ALDH1A1MAPTLMNAHPGD | |
| SCHEMBL661852 | 0.61 | CTNNB1 (0.34) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL660037 | 0.60 | NPC1 (0.36) | SMN1; SMN2HTTKMT2AALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427432-A2 | NOVEL HETEROCYCLIC COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
| WO-2010128528-A2 | NOVEL HETEROCYCLIC COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | SMN1; SMN2 640/4885HTT 75/4885KMT2A 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.